Seed · Biotech · Lausanne, Switzerland · Founded 2020 · 9–10 employees
HemostOD is developing universal blood platelets using proprietary bioreactor technology to address global platelet shortages that affect cancer, trauma, and bleeding disorder patients. The company creates donor-free platelets from immortalized stem cells, eliminating contamination risks and immune complications. Founded in 2020 at EPFL Innovation Park, they have raised CHF 6 million total including a recent CHF 4.3 million seed extension in 2025. The technology aims to transform transfusion medicine by providing on-demand platelet production with a potential market of USD 5.7 billion globally.
No open roles listed right now.